CBD meets diabetes drugs: could this combo be a game changer for weight and sugar?

NCT ID NCT06648031

Completed Disease control Sponsor: Lexaria Bioscience Corp. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a special form of cannabidiol (CBD) called DehydraTECH, alone or combined with GLP-1 drugs (like Ozempic), in 148 overweight or obese adults with prediabetes or type 2 diabetes. The main goal was to check safety and how the body processes the drugs, while also looking at effects on blood sugar and weight. Results will help decide if this combination deserves larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREDIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE2DIABETES

Contacts and locations

Locations

CMAX Clinical Research

Adelaide, South Australia, 5000, Australia
Canopy Clinical Sutherland

Miranda, New South Wales, 2228, Australia
Canopy Clinical Wollongong

Wollongong, New South Wales, 2500, Australia
Emeritus - Melbourne

Camberwell, Victoria, 3124, Australia
Emeritus - Sydney

Botany, New South Wales, 2019, Australia
Paratus Clinical Brisbane Pty Ltd

Herston, Queensland, 4006, Australia
Paratus Clinical Pty Ltd, Blacktown Trial Clinic

Blacktown, New South Wales, 2148, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.